For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development (including related party amounts of 72 and 228, respectively) | 14,379 | 13,639* | 14,589 | 15,738 |
| General and administrative (including related party amounts of 85 and 134, respectively) | 5,327 | 4,509* | 4,722 | 5,831 |
| Total operating expenses | 19,706 | 18,147 | 19,311 | 21,569 |
| Loss from operations | -19,706 | -18,147* | -19,311 | -21,569 |
| Interest income | 2,070 | 2,475* | 2,314 | 2,486 |
| Net loss | -17,636 | -15,672 | -16,997 | -19,083 |
| Basic EPS | -0.29 | -0.269 | -0.3 | -0.34 |
| Diluted EPS | -0.29 | -0.269 | -0.3 | -0.34 |
| Basic Average Shares | 61,434,457 | 58,180,189 | 56,950,999 | 56,859,388 |
| Diluted Average Shares | 61,434,457 | 58,180,189 | 56,950,999 | 56,859,388 |
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)